戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 whom 2 eventually developed overt macrophage activation syndrome).
2 hagocytic lymphohistiocytosis and macrophage activation syndrome.
3 scular coagulation as features of macrophage activation syndrome.
4 tablished, and 1 patient had a monoclonal MC activation syndrome.
5 fe-threatening condition known as macrophage activation syndrome.
6 ic mastocytosis but not monoclonal mast cell activation syndrome.
7  promising diagnostic markers for macrophage activation syndrome.
8 with those in patients with acute macrophage activation syndrome.
9 dentify patients with subclinical macrophage activation syndrome.
10 ssociated with the development of macrophage activation syndrome.
11 ning sample was diagnosed with monoclonal MC activation syndrome.
12 tionship between systemic JIA and macrophage activation syndrome.
13 bances in cytokine signaling, and macrophage activation syndromes.
14 arthritis is the association with macrophage activation syndrome, a life-threatening complication cau
15 anakinra is effective in treating macrophage activation syndrome, a similar entity with fever, dissem
16 gulation and the relation between macrophage activation syndrome and hemophagocytic lymphohistiocytos
17 rstanding of the relation between macrophage activation syndrome and other clinically similar hemopha
18  in the last decade, many areas of mast cell activation syndrome are in need of research.
19 n sera from 7 patients with acute macrophage activation syndrome complicating systemic JIA and 16 pat
20 ha and sCD163 in diagnosing acute macrophage activation syndrome complicating systemic juvenile idiop
21       Hence, sepsis patients with macrophage activation syndrome features may benefit from interleuki
22 andomized trial using features of macrophage activation syndrome for mortality risk stratification sh
23 (including those with subclinical macrophage activation syndrome) from those with normal or only mode
24                       Clinically, macrophage activation syndrome has strong similarities with familia
25 ytokines that are associated with macrophage activation syndrome/hemophagocytic lymphohistiocytosis,
26 uccessful use of cyclosporine for macrophage activation syndrome in JRA.
27 useful tool for identifying early macrophage activation syndrome in patients with systemic JIA.
28 n, pathogenesis and management of macrophage activation syndrome in systemic onset juvenile idiopathi
29  elucidate the pathophysiology of macrophage activation syndrome in systemic onset juvenile idiopathi
30 in expression may be a feature of macrophage activation syndrome in systemic-onset juvenile rheumatoi
31 ute to the increased incidence of macrophage activation syndrome in these patients.
32   A total of 335 patients presenting with MC activation syndrome, including 143 insectISMs(-), 72 ISM
33  clinical features of established macrophage activation syndrome, including ferritin levels.
34                                   Macrophage activation syndrome is a life-threatening complication s
35                                   Macrophage activation syndrome is characterized by an overwhelming
36                                   Macrophage activation syndrome is the rheumatic disease-associated
37 tic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are 2 similar diseases charact
38 tic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are both characterized by dysr
39                        The deadly macrophage activation syndrome (MAS) constitutes one of the few rhe
40  HLH, using modified HLH-2004 and macrophage activation syndrome (MAS) criteria.
41                                   Macrophage activation syndrome (MAS) is a devastating cytokine stor
42                                   Macrophage activation syndrome (MAS) is an acute episode of overwhe
43               The pathogenesis of macrophage activation syndrome (MAS) is not clearly understood: a l
44                                   Macrophage activation syndrome (MAS), a major cause of morbidity an
45 ytosis (HLH), and the HLH-sibling macrophage activation syndrome (MAS).
46 -onset recurrent fever flares and macrophage activation syndrome (MAS).
47 tic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS).
48 -targeting drugs, the diagnosis of mast cell activation syndrome (MCAS) is appropriate.
49 proposed to interpret acute MCT in mast cell activation syndrome (MCAS).
50                            Primary mast cell activation syndromes (MCAS) are a group of disorders pre
51 hagocytic lymphohistiocytosis and macrophage activation syndrome, natural killer and cytotoxic cell d
52                               The macrophage activation syndrome occurred in 7 patients; infections w
53 om showed evidence of subclinical macrophage activation syndrome (of whom 2 eventually developed over
54 nal mast cell disorder (monoclonal mast cell activation syndrome or systemic mastocytosis) and thus c
55 n disorders (inflammasomopathies), NF-kappaB activation syndromes, protein misfolding disorders, comp
56                                    Mast cell activation syndrome refers to a group of disorders with
57  these 5 patients developed overt macrophage activation syndrome several months later.
58  sIL-2Ralpha in the patients with macrophage activation syndrome was 19,646 pg/ml (interquartile rang
59  level of sCD163 in patients with macrophage activation syndrome was 23,000 ng/ml (IQR 14,191), compa
60 herISMs(-)), 56 ISMs(+), and 64 nonclonal MC activation syndrome, were studied.
61                       A monoclonal mast cell activation syndrome with aberrant mast cells (MC) at ext

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。